MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.esmoop.2026.108246

Медицинская библиотека · ESMO open · 2026

Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.

Hsu C-C, Yeh K-Y, Chang C-F, Wu C-F, Kou H-W, Chen Y-F, Chen M-Y, Hsu J-T, Yeh C-N, Wu C-E, Huang W-K, Ku C-H, Lan C-C, Hsieh C-L, Hsu Y-W, Hsieh C-H, Chang L-L, Huang S-C, Chen T-C, Chen J-S, Hung Y-S, Chou W-C

СтатьяМногоцентровое исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer characterized by features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). As cHCC-CCA prognosis often falls between HCC and CCA or resembles CCA, we compared the outcomes of durvalumab plus gemcitabine-cisplatin (GCD) in patients with cHCC-CCA and CCA in a real-world setting.

MATERIALS AND

METHODS

This retrospective multicenter study included patients with histologically confirmed unresectable or metastatic CCA or cHCC-CCA who underwent first-line GCD at four centers in Taiwan between 2021 and 2025. Outcomes included overall survival (OS), progression-free survival (PFS), tumor response, and safety. Propensity score matching (PSM) was performed to balance baseline characteristics.

RESULTS

Among the 175 patients, 154 had CCA and 21 had cHCC-CCA. Before matching, patients with cHCC-CCA more frequently had elevated α-fetoprotein levels and poor biliary drainage; however, these imbalances were resolved after PSM. Before PSM, patients with CCA and cHCC-CCA had median OS of 13.3 months [95% confidence interval (CI) 9.5-17.1] and 13.8 months (95% CI 2.1-25.6, P = 0.60) and median PFS of 5.1 months (95% CI 4.7-5.5) and 5.3 months (95% CI 3.1-7.5, P = 0.40), respectively. After PSM, both OS and PFS rates were similar between the groups. The objective response rate was higher in the cHCC-CCA group (38.1% versus 23.4% before PSM, P = 0.15; 38.1% versus 23.8% after PSM, P = 0.24), whereas the disease control rates were identical (66.7% after PSM). The most common toxicities were hematologic events, with both groups demonstrating similar rates of anemia, thrombocytopenia, leukopenia, and neutropenia.

CONCLUSIONS

This study demonstrates that patients with cHCC-CCA derive comparable clinical benefit from GCD as those with CCA in terms of efficacy and safety. These findings support the incorporation of immunochemotherapy into the treatment framework for cHCC-CCA and provide a rationale for its use in clinical practice.

Для цитирования: Hsu C-C, Yeh K-Y, Chang C-F, Wu C-F, Kou H-W, Chen Y-F, Chen M-Y, Hsu J-T, Yeh C-N, Wu C-E, Huang W-K, Ku C-H, Lan C-C, Hsieh C-L, Hsu Y-W, Hsieh C-H, Chang L-L, Huang S-C, Chen T-C, Chen J-S, Hung Y-S, Chou W-C. Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.. ESMO open. 2026. DOI: 10.1016/j.esmoop.2026.108246.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.